key: cord-0837026-pcvuzu3v
authors: Wang, Qian; Nair, Manoj S.; Anang, Saumya; Zhang, Shijian; Nguyen, Hanh; Huang, Yaoxing; Liu, Lihong; Ho, David D.; Sodroski, Joseph G.
title: Functional differences among the spike glycoproteins of multiple emerging SARS-CoV-2 variants of concern
date: 2021-11-01
journal: iScience
DOI: 10.1016/j.isci.2021.103393
sha: 286cdd9bf0ff09b6bbbed4fcf1b4019ede9e9bfb
doc_id: 837026
cord_uid: pcvuzu3v

We compared the functional properties of spike (S) glycoproteins from the original SARS-CoV-2 strain (D614) (Wuhan, China), the globally dominant D614G strain and emerging geographic variants: B.1.1.7 (United Kingdom), B.1.351 (South Africa), P.1 (Brazil), and B.1.1.248 (Brazil/Japan). Compared with D614G, the emerging variants exhibited increased affinity for the receptor, ACE2, and increased ability to infect cells with low ACE2 levels. All variants lost infectivity similarly at room temperature and 37°C; however, in the cold, B.1.1.7 was more stable, and P.1 and B.1.1.248 were less stable. Shedding of the S1 glycoprotein from the spike contributed to virus inactivation in the cold. B.1.351, P.1 and B.1.1.248 were neutralized by convalescent and vaccinee sera less efficiently than the other variants. Spike glycoprotein properties such as requirements for ACE2 levels on the target cell, functional stability in the cold and resistance to host neutralizing antibodies potentially contribute to the outgrowth of emerging SARS-CoV-2 variants.

The COVID-19 pandemic caused by the SARS-CoV-2 coronavirus has severely impacted global health, world economy and quality of life (Hu et al., 2021; Nicola et al., 2020; Wang et al., 2020) . Over the past several months, intensive efforts have been placed on vaccine production and distribution, raising hope for the possibility of curtailing and controlling the virus' spread (Krammer, 2020; Ng et al., 2020) . Multiple vaccine approaches employing SARS-CoV-2 spike (S) glycoprotein immunogens have demonstrated significant clinical efficacy (Anderson et al., 2020; AstraZeneca, 2021; Baden et al., 2021; Johnson, 2021; Novavax, 2021; Polack et al., 2020; Voysey et al., 2021; Xia et al., 2021) . While the results are promising, the virus has continued to evolve; as early as November of 2020, the first reports of global variants with higher transmissibility rates were released (du Plessis et al., 2021; Kupferschmidt, 2021) . Changes in the genome resulting from the replication of RNA viruses like SARS-CoV-2 are not unexpected, but indications that these new strains of SARS-CoV-2 exhibit increased transmissibility, pathogenicity and/or susceptibility to neutralizing antibodies are concerning (Davies et al., 2021a; Davies et al., 2021b; Tegally et al., 2020) . Consequently, the Centers for Disease Control and Prevention has designated several newly emergent strains (B.1.1.7, B.1.351, P.1 and B.1.427) as 'variants of concern' (CDC, 2021).

Shortly after the beginning of the COVID-19 pandemic, a SARS-CoV-2 strain with a D614G alteration in the S glycoprotein arose that exhibited greater spike stability and infectivity than the original virus from Wuhan, China (Korber et al., 2020; Li et al., 2020; Zhang et al., 2021; Zhang et al., 2020) . The D614G variant quickly became globally J o u r n a l P r e -p r o o f dominant (Korber et al., 2020) . Additional SARS-CoV-2 variants have emerged as descendants of this D614G strain, including B.1.1.7 (identified in the United Kingdom), B.1.351 (identified in South Africa), P.1 (prevalent in Brazil), and B.1.1.248 (identified in travelers to Japan from Brazil) (Fujino et al., 2021; Kupferschmidt, 2021; National Institute of Infectious Diseases, 2021; Tegally et al., 2020) . Studies have demonstrated that the observed changes in the S glycoproteins of these variants decrease the sensitivity of the virus to neutralization by monoclonal antibodies or vaccine-induced antisera (Hoffmann et al., 2021; Wang et al., 2021a; Wang et al., 2021b; Wang et al., 2021c) . Clinical trials of some vaccines have suggested a reduction in efficacy against the B.1.351 variant (Voysey et al., 2021; Wang et al., 2021d; Wu et al., 2021) .

Although each of the emerging SARS-CoV-2 variants exhibits changes throughout their proteome, such changes particularly cluster in the S glycoprotein, the viral surface protein that mediates virus entry and thus represents the predominant target of antibodies. The coronavirus spike is a glycosylated trimer composed of two subunits, S1 and S2 (Bosch et al., 2003) . The receptor-binding S1 subunit is relatively exposed, whereas much of S2 is buried as a transmembrane subunit. As such, neutralizing antibody responses are primarily directed against the S1 subunit (Isho et al., 2020) . The S1 subunit is further subdivided into an N-terminal domain (NTD) and receptor-binding domain (RBD), both of which are targets of neutralizing antibodies .

Several studies have examined the impact of spike variation in emerging SARS-CoV-2 strains on virus susceptibility to host antibody responses (Hoffmann et al., 2021; Wang et al., 2021a; Wang et al., 2021b; Wang et al., 2021c) , but fewer studies J o u r n a l P r e -p r o o f have examined the functional properties of the mutant S glycoproteins. The multitude of changes in the S glycoproteins that become fixed in these variants supports their potential importance to transmission, pathogenesis and/or immune evasion. Indeed, some of the observed changes enhance S glycoprotein binding to the receptor, angiotensin-converting enzyme 2 (ACE2) (Gobeil et al., 2021; Laffeber et al., 2021) .

Here, we examine the functional properties of the S glycoproteins of the emerging SARS-CoV-2 variants B.1.1.7, B.1.351, P.1, and B.1.1.248. Using vesicular stomatitis virus (VSV) and human immunodeficiency virus (HIV-1) pseudotypes, we evaluated the expression, post-translational processing, infectivity, stability at various temperatures, and sensitivity to neutralization of the variants. The overall level of expression, processing and glycosylation of the variant S glycoproteins in cell lysates and pseudovirus particles were similar to those of the original (D614) SARS-CoV-2 strain from Wuhan, China. Notably, compared with the D614 S glycoprotein, the S glycoproteins of the emerging variants required less ACE2 receptor expression on the target cell to mediate virus entry. This enhanced infection efficiency was in part explained by a 2-9-fold increase in ACE2 binding affinity. Although the infectivity of the S glycoprotein-pseudotyped viruses decayed comparably at room temperature and 37°C, marked differences in susceptibility to cold inactivation, which reflects the stability of the trimeric spike, were observed. At 0°C, P.1 and B.1.1.248 spontaneously shed the S1 glycoprotein from the trimer and lost infectivity, whereas B.1.1.7 exhibited greater spike stability and was more resistant to cold inactivation than D614. The authentic B.1.1.7 SARS-CoV-2 variant resisted cold inactivation more than the other viruses tested. Soluble ACE2 (sACE2) binding at 37°C resulted in the shedding of the S1 glycoprotein from the trimer of all strains tested; however, strain-dependent J o u r n a l P r e -p r o o f

particles. In this study, we compare the functional phenotypes of the S glycoproteins of the newly emergent SARS-CoV-2 variants B.1.1.7, B.1.351, P.1, and B.1.1.248 with those of the early/founder virus (D614) and the globally prevalent D614G variant (Korber et al., 2020; Volz et al., 2021) . (Tegally et al., 2020) and has 9 S glycoprotein changes in addition to D614G, including three in the RBD and several in the NTD. The P.1 variant is prevalent in Brazil; in addition to D614G, P.1 has 10 changes, three of which are similar to those in the RBD of B.1.351 (Fujino et al., 2021) . P.1 also has five changes in the NTD, two of which introduce new potential N-linked glycosylation sites. Compared with the P.1 variant, the B.1.1.248 variant, which was identified in travelers to Japan from Brazil, has one change in HR2 (National Institute of Infectious Diseases, 2021).

We studied the expression, processing, subunit association and incorporation into pseudotyped virus particles of the variant SARS-CoV-2 S glycoproteins. We generated VSV and lentivirus (HIV-1) particles as previously described (Schmidt et al., J o u r n a l P r e -p r o o f 8 2020). The D614 and variant S glycoproteins were expressed in 293T cells followed by VSV∆G infection or were expressed in combination with lentiviral vector constructs.

Subsequently, the S glycoproteins in the cell lysates and on the VSV/lentiviral particles were examined by Western blot. The uncleaved S precursor, as well as the cleaved S1 and S2 proteins, were evident in the cell lysates and on VSV/lentiviral particles (Fig.   1B ). The majority of the S glycoproteins incorporated into VSV/lentiviral particles was cleaved into S1 and S2, whereas a higher ratio of uncleaved S precursor was present in the cell lysates. Most of the variant S glycoproteins were processed and incorporated into viral particles comparably; the proteolytic processing of D614G was slightly more efficient than that of D614 (Fig. 1C ), as has been previously seen (Nguyen et al., 2020) . The S1/S2 ratio on VSV and lentiviral particles was higher for B.1.1.7 than that of the D614 and other variants (Fig. 1D) , suggesting a tighter association of the B.1.1.7 S1 glycoprotein with the viral spike.

To study the glycosylation of the SARS-CoV-2 D614 and variant S glycoproteins, cell lysates and VSV/lentiviral particles from S-expressing 293T cells were treated with PNGase F and Endo Hf. PNGase F removes almost all types of Nlinked glycosylation, including high-mannose, hybrid, bi-, tri-, and tetra-antennary glycans, whereas Endo Hf selectively removes high-mannose and some hybrid types of N-linked carbohydrates. The glycosylation patterns of S glycoproteins on pseudotyped VSV particles ( Fig. 2A ) and lentiviral particles (Fig. 2B) were similar. S glycoprotein precursors in 293T cell lysates were mainly modified by high-mannose glycans. In contrast, the cleaved S1 and S2 glycoproteins contained mostly complex J o u r n a l P r e -p r o o f carbohydrates. The ratio of cleaved:uncleaved S glycoproteins in viral particles was increased compared with that in cell lysates. Multiple S1 and S2 bands from the cell lysate samples treated with glycosidases were detected, indicating diverse posttranslational modification of the S1 and S2 subunits. Following PNGase F digestion, the S2 glycoproteins incorporated into virus particles were more homogeneous than those in cell lysates.

The untreated and the Endo Hf-treated S1 from P.1 and B.1.1.248 migrated slightly slower than that of D614G. The two additional potential N-linked glycosylation sites created by the T20N and R190S changes in the NTDs of P.1 and B.1.1.248 S1 glycoproteins likely account for the observed higher molecular weight. B.1.1.7 S1, which has a deletion of three amino acids compared to D614G, as well as the S2 glycoprotein of P.1 and B.1.1.248, also migrated slower after Endo Hf but not PNGase F treatment, highlighting their additional modification by complex carbohydrates compared with that of D614G.

Analysis of authentic SARS-CoV-2 particles confirmed that the vast majority of the S, S1 and S2 glycoproteins incorporated into virions are modified by complex carbohydrates for all strains examined (Fig. 2C ).

SARS-CoV-2 variants. We examined the efficiency of cell-cell fusion mediated by the D614 and variant S glycoproteins. We used two platforms to study this function, an alpha-complementation assay and a Tat-based assay. In the former assay, COS-1 effector cells transiently expressing ⍺-gal and the S glycoprotein were co-cultured for J o u r n a l P r e -p r o o f allowing quantitation of cell-cell fusion by measurement of β-galactosidase activity (Nguyen et al., 2020) . In the latter assay, 293T cells expressing Tat and the S glycoprotein were used as donor cells, while TZM-bl cells stably expressing human ACE2 (TZM-bl-ACE2) were used as recipient cells. Cell-cell fusion of the cocultured donor and recipient cells results in activation of luciferase by HIV-1 Tat. In both systems, the SARS-CoV-2 S glycoprotein variants mediated nearly equivalent levels of cell-cell fusion (Fig. 3A ). The relative cell-cell fusion activities of the S glycoprotein variants were not changed by varying target cell ACE2 levels ( Fig. S1 ) or by coculturing the donor and recipient cells for longer periods of time (data not shown).

To investigate the ability of the variant SARS-CoV-2 S glycoproteins to mediate virus entry, we conducted single-round infection of target cells by S-pseudotyped VSV and lentiviral particles, as previously described (Schmidt et al., 2020) . Infection by VSV pseudotypes was measured on Vero-E6 and 293T-ACE2 cells (Fig. 3B) , and infection by lentivirus pseudotypes was measured only on 293T-ACE2 cells, as HIV-1 cannot infect Vero-E6 cells. Consistent with previous reports (Korber et al., 2020; Li et al., 2020; Nguyen et al., 2020; Zhang et al., 2021; Zhang et al., 2020) , D614G exhibited increased infectivity for both Vero-E6 and 293T-ACE2 cells compared with that of D614 (Fig. 3B ). J o u r n a l P r e -p r o o f ACE2 binding and sACE2-induced S1 shedding of variant spikes. The above results suggest that changes in the S glycoproteins of emerging SARS-CoV-2 variants may affect their interaction with ACE2. We therefore evaluated the binding of soluble S glycoprotein trimers corresponding to D614G and four variants to the sACE2-Fc protein by ELISA (Figs. 4A and 4B). The sACE2-Fc protein is a soluble form of the ACE2 receptor fused to the immunoglobulin Fc. All four variants exhibited modest (1.7 to 8.2-fold) increases in the estimated binding affinity for sACE2-Fc, relative to that of D614G.

We also compared the neutralizing activity of a dimeric soluble ACE2 The noncovalent association of S1 and S2 allows spontaneous or soluble ACE2-induced shedding of S1 from the spike trimer on SARS-CoV-2 virions, leading to functional inactivation of the viral spike proteins (Nguyen et al., 2020; Zhang et al., 2020) . To examine potential differences in S1 shedding from SARS-CoV-2 variant spikes, we incubated S-pseudotyped VSV particles with various concentrations of soluble ACE2 (sACE2) for one hour at 37°C and on ice. Viruses were then pelleted, J o u r n a l P r e -p r o o f washed and lysed, after which the viral lysates were Western blotted with antibodies against S1, S2 and ACE2 (Figs. 4D and 4E) . We quantified the blots and examined the S1/S2 ratio (Fig. 4F ) as an indicator of S1/S2 association. At 37°C, sACE2 induced S1 shedding from all the VSV pseudotypes, with D614G, B.1.351, P.1 and B.1.1.248 shedding S1 slightly more efficiently than D614 and B.1.1.7. Interestingly, the pattern of sACE2-induced S1 shedding differed on ice, with D614, D614G and B.1.351 exhibiting more efficient S1 shedding than B.1.1.7, P.1 and B.1.1.248. Thus, while the responses of the variant spikes to sACE2 differed only modestly at 37°C, significant differences in this property were revealed at a colder temperature. As the cold sensitivity of the SARS-CoV-2 variants could hypothetically be related to the shedding of the S1 glycoprotein from the spike, we incubated each of the VSV pseudotypes on ice, at 4°C, at room temperature and at 37°C for two days and then quantified S1 shedding from the viral particles (Figs. 5C, 5D and S2B). The S1/S2 ratio for each SARS-CoV-2 variant is summarized in Fig. 5E , with a lower ratio indicating greater S1 shedding. Spontaneous S1 shedding at 0 and 4°C for D614, P.1 and B.1.1.248 was significantly greater than that of D614G, B.1.1.7 and B.1.351. The higher rate of S1 shedding for P.1 and B.1.1.248 on ice and at 4°C likely contributes to their lower infectivity after prolonged incubation in the cold (Figs. 5A, 5B and S2A).

Conversely, the B.1.1.7 variant was relatively resistant to spontaneous S1 shedding at 0 and 4°C, which is consistent with its higher infectivity after prolonged exposure to cold temperatures (Figs. 5A, 5B and S2A). D614, D614G and B.1.351 were inactivated similarly on ice and at 4°C, but exhibited different levels of S1 shedding, suggesting that cold inactivation involves additional factors besides S1 shedding. With the exception of D614G, S1 shedding for each S glycoprotein variant was less at room temperature and 37°C than on ice. Collectively, these results suggest that factors in addition to S1 shedding can affect the infectivity of the variant S-pseudotyped viruses exposed to different temperatures.

We evaluated the effect of cold temperature on the infectivity and composition of authentic SARS-CoV-2 variants. The B.1.1.7 SARS-CoV-2 variant retained infectivity at 4°C better than the D614G and P.1 variants (Fig. 5F ). As was seen for the VSV pseudotypes, the authentic P.1 SARS-CoV-2 variant exhibited more S1

shedding over time at 4°C than the D614G and B.1.1.7 variants (Fig. 5G) . Thus, authentic SARS-CoV-2 variants exhibit differences in sensitivity to cold exposure.

Some SARS-CoV-2 variants are more resistant to convalescent COVID-19 patient sera and vaccinee sera. As we observed differences among the relative infectivity of the S glycoprotein variants when differing levels of ACE2 were expressed on target cells, we hypothesized that the choice of target cells might also differentially affect antibody neutralization. We used Vero-E6 and 293T-ACE2 cells (shown in Figs.

3C and D to have moderate and high levels of ACE2, respectively) as target cells in the neutralization assays. We tested the neutralization of VSV pseudotypes and authentic SARS-CoV-2 variants by two groups of sera: 1) sera collected from March to June 2020 from convalescent COVID-19 patients from New York City (Table S1); and 2) sera from individuals fully vaccinated with two doses of the Moderna COVID-19 vaccine. Both sets of sera recognized a SARS-CoV-2 S2P trimer; the titers of trimer-reactive antibodies were, on average, higher in the vaccinees than in the COVID-19 patients (Fig. S3 ). In general, the neutralization titers of the sera were higher for Vero-E6 cells compared with those for 293T-ACE2 cells (Figs. 6, S4 and S5). Qualitatively, the patterns of neutralization in the two target cells were similar.

Consistent with other studies (Wang et al., 2021a; Wang et al., 2021b; Wang et al., 2021c) , Proteolytic cleavage of the variant S glycoprotein precursors, which are decorated with high-mannose carbohydrates, occurs in the Golgi, as evidenced by the extensive modification of the cleaved S1 and S2 glycoproteins by complex glycans.

For all variants, we observed enrichment of the cleaved S1 and S2 glycoproteins in the pseudovirus particles compared with cell lysates. Thus, most of the S glycoproteins incorporated into VSV or lentiviral particles have passed through the Golgi apparatus. (Tian et al., 2021) . As ACE2 expression levels vary depending on the location and differentiation state of human airway epithelial cells (Jia et al., 2005; Ortiz et al., 2020) , the ability to support infection of cells with low ACE2 potentially enhances the tropism, transmission and/or pathogenicity of SARS-CoV-2 variants.

The infectivity of VSV vectors pseudotyped by the variant S glycoproteins decayed equivalently at room temperature and 37°C, with half-lives of approximately 24 and 12 hours, respectively. These half-lives are much shorter than the reported half-life of infectious VSV (28 and 7 days at room temperature and 37°C, respectively) (Zimmer et al., 2013) ; therefore, functional inactivation of the SARS-CoV-2 S glycoproteins on the VSV pseudotypes likely is the predominant determinant of the observed loss of infectivity at these temperatures. Spontaneous S1 shedding from the spike glycoprotein was apparently not required for functional inactivation at room temperature or 37°C, given the significant amount of S1 remaining on the virus particles after 48 hours at these temperatures.

Intriguing differences among the phenotypes of the emerging SARS-CoV-2 variant S glycoproteins were revealed in the cold. Incubation on ice or at 4°C led to J o u r n a l P r e -p r o o f rapid loss of infectivity of the P.1 and B.1.1.248 pseudotypes, in comparison to the D614, D614G and B.1.351 viruses. In contrast, the infectivity of the B.1.1.7 pseudotype was more stable at 0 and 4°C than that of the other viruses. Likewise, the authentic B.1.1.7 SARS-CoV-2 variant exhibited a longer half-life at 4°C than the authentic D614G and P.1 variants. We found that incubation of the pseudotyped viruses on ice or at 4°C led to a dramatic loss of the S1 glycoprotein from the P.1 and B.1.1.248 spikes, whereas the B.1.1.7 spike was minimally affected under the same conditions. These results suggest that differential destabilization of the variant S glycoprotein spikes leading to S1 shedding contributes to the observed inactivation of virus infectivity in the cold. However, we note that, as previously seen (Nguyen et al., 2020) , the D614G spike is more stable and sheds S1 less at 0 or 4°C than the D614

spike, yet these two variants exhibit minimal differences in the rate of decay of infectivity at these temperatures. Apparently, maintaining an intact S glycoprotein spike after prolonged exposure to cold temperatures is not sufficient for retention of spike function.

Some oligomeric proteins undergo denaturation at temperatures near 0°C as a result of weakening of intersubunit interactions (Lopez et al., 2008; Privalov, 1990; Tsai et al., 2002) . For example, HIV-1 infectivity can be attenuated by incubation on ice, and the different sensitivities of HIV-1 strains to cold inactivation are determined by their envelope glycoproteins (Kassa et al., 2009a; Medjahed et al., 2013) . Although the cold denaturation of some proteins is reversible, cold-induced changes in high-potentialenergy, metastable viral envelope glycoproteins typically lead to irreversible transitions to low-energy states incapable of mediating membrane fusion. Of interest, sensitivity of HIV-1 strains to cold is related to the propensity of their envelope J o u r n a l P r e -p r o o f glycoproteins to make the transition from the pretriggered conformation to the receptor-bound conformation (Kassa et al., 2009b) . If the sensitivity of the P.1 and B.1.1.248 variants to cold inactivation likewise indicates an increased propensity to sample receptor-bound conformations, this tendency could contribute to the higher relative infectivity of these variants on cells with low ACE2 levels. Indeed, HIV-1 envelope glycoprotein mutants with changes that destabilize the pretriggered conformation are better able to support virus entry into cells with low levels of the CD4 receptor (Haim et al., 2011; Herschhorn et al., 2016) .

The ability to withstand low temperatures could have practical value for a respiratory virus that is horizontally transmitted by aerosols/droplets and is potentially exposed to a range of environmental conditions. Although naturally transmitted SARS-CoV-2 is not typically exposed to near-freezing temperatures for prolonged periods of time, cold resistance is a surrogate indicator of the ability of the functional viral spike to resist conformational changes induced by various forms of environmental stress (Lopez et al., 2008; Privalov, 1990; Tsai et al., 2002) . For example, as a virus transmitted by sexual or blood contacts, HIV-1 is not naturally exposed to cold temperatures; nonetheless, viruses with cold-sensitive HIV-1 envelope glycoproteins revert to cold- We examined the sensitivity of authentic SARS-CoV-2 variants, as well as VSV vectors pseudotyped by the variant S glycoproteins, to neutralization by sera from convalescent COVID-19 patients and recipients of the Moderna COVID-19 vaccine.

The neutralization profile of B.1.1.7 was similar to that of D614 and D614G, whereas B.1.351, P.1 and B.1.1.248 were less sensitive to these antisera. The K417N and E484K changes in the S1 RBD have been shown to contribute to escape from neutralizing antibodies (Chen et al., 2021; Wang et al., 2021a; Wang et al., 2021b; Wang et al., 2021c) . We found that serum neutralization was generally more effective with target cells that express lower levels of ACE2. This supports the notion that ACE2 receptors on the target cell and many neutralizing antibodies compete for binding to the S1 RBD.

Differing abilities of the spike glycoprotein variants to utilize low levels of target cell receptor, to maintain structural and functional integrity in the cold, and to resist host neutralizing antibodies potentially contribute to the adaptation of emerging SARS-CoV-2 variants to their environments. Understanding these aspects of SARS-CoV-2 spike biology should assist attempts to control the COVID-19 pandemic. 

We thank Elizabeth Carpelan for manuscript preparation. This study was supported by the National Institutes of Health and by a gift from the late William F. McCarty-Cooper.

The authors declare no competing interests. (B) HEK293T cells producing VSV (upper panels) and lentiviral (lower panels) particles pseudotyped with the indicated SARS-CoV-2 S glycoproteins were used to prepare cell lysates (left panels) and viral particles (right panels), which were Western blotted with rabbit anti-S1 and anti-S2 antibodies. The samples were also Western blotted with anti-VSV NP (upper panels), anti-HIV p17/p24/p55 (lower panels) and

anti-GAPDH antibodies. The Western blots shown are representative of those obtained in four independent experiments. Cells transfected with the pcDNA3.1 vector were used as a negative control.

(C) Processing indices were calculated from Western blots of cell lysates from multiple experiments, as described (Nguyen et al., 2020) . The processing index of each S glycoprotein variant was compared with that of D614 using a Student's unpaired t test (*p<0.05; nsnot significant). Data are represented as mean +/-SEM. J o u r n a l P r e -p r o o f (D) The intensities of the S1 and S2 glycoprotein bands in Western blots derived from four independent experiments described in (B) were measured. The average S1/S2 ratio was calculated and compared with that of D614G. Statistical analysis was performed using a Student's unpaired t test (*p<0.05). Data are represented as mean +/-SEM.

HEK293T cells producing VSV (A) and lentiviral (B) particles pseudotyped with the indicated SARS-CoV-2 S glycoproteins were used to prepare cell lysates (left panels) and viral particles (right panels). The cell lysates and viral particle preparations were treated with PNGase F and Endo Hf, and the deglycosylated samples were Western blotted with rabbit anti-S1 and anti-S2 antibodies. Cells transfected with the pcDNA3.1 vector were used as a negative control. In (C), authentic virus particles from the indicated SARS-CoV-2 strains were prepared from the supernatants of infected Vero-E6 cells. Virion lysates were treated with PNGase F or Endo Hf and analyzed as described above. The deglycosylated forms of the S glycoprotein precursor (dS), S1 subunit (dS1) and S2 subunit (dS2) Statistical significance in A, B and E was evaluated with a Student's unpaired t test (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; nsnot significant). 

were incubated with the indicated concentrations of soluble ACE2 (sACE2) for one hour at 37°C (D) and on ice (E). Pelleted VSV particles were analyzed by Western blotting with antibodies against S1, S2, ACE2 and VSV NP.

(F) The intensities of the S1 and S2 glycoprotein bands in (D) and (E) were measured and the S1/S2 ratios for each concentration of sACE2 are shown. particles were analyzed by Western blotting with antibodies against S1, S2 and VSV NP. In (D), VSV pseudotypes that were not exposed to the different temperatures for 48 hours served as controls (Ctrl). The results shown are representative of those obtained in three independent experiments. See also Figure S2B .

The intensities of the S1 and S2 glycoprotein bands in (D) were measured. The S1/S2 ratios are shown for each variant relative to the ratio for the control sample of the pseudoviruses. The means and standard deviations derived from three independent experiments are shown. The S1/S2 ratio for each variant was compared J o u r n a l P r e -p r o o f with that of D614G. Statistical significance was evaluated with a Student's t test (*p<0.05; **p<0.01; ****p<0.0001; nsnot significant). Pelleted viral particles were analyzed by Western blotting with antibodies against S1 and S2. Viruses that were not exposed to 4˚C served as controls (Ctrl). See also Figure S2B . paired t test (*p<0.05; **p<0.01; ***p<0.001; and ****p<0.0001; nsnot significant).

The primary data shown in Figs. 1, 3, 4 , 5 and 6 were used to calculate average values relative to those obtained for the D614 S glycoprotein. Decreases in the phenotypes relative to those of D614 are shaded red to a degree dependent on the level of the decrease. Increases in the phenotypes relative to those of D614 are shaded blue to a degree dependent on the level of the increase.

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Joseph G. Sodroski (joseph_sodroski@dfci.harvard.edu).

All requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Joseph G. Sodroski (joseph_sodroski@dfci.harvard.edu). This includes selective cell lines, plasmids, antibodies, viruses, serum and proteins. All reagents will be made available on request after completion of a Material Transfer Agreement.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Data reported in this paper will be shared by the lead contact upon request.

This paper does not report original codes.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Table S1 . Sera were obtained from 6 participants in a phase-I clinical trial of the Moderna SARS-CoV-2 mRNA-1273 vaccine conducted at the NIH, under a NIH IRB-approved protocol (Anderson et al., 2020) . . Two micrograms of each S2P trimer was analyzed on a NuPAGE Bis-Tris protein gel (Invitrogen, Waltham, MA) run at 200 V using MES buffer, after which the gel was stained with Coomassie Blue dye.

To generate VSV-based vectors pseudotyped with SARS-CoV-2 S glycoproteins, 5 × 10 6 HEK293T cells were plated in a 10-cm dish one day before transfection. Six micrograms of the SARS-CoV-2 S glycoprotein plasmid was transfected into the HEK293T cells using Polyethylenimine (Polysciences, Warrington, PA). Twenty-four hours later, the cells were infected at a multiplicity of infection of 3 to 5 with rVSV-∆G pseudovirus bearing a luciferase gene (Kerafast, Boston, MA) for 2 h at 37°C and then J o u r n a l P r e -p r o o f washed three times with PBS. Cell supernatants containing pseudoviruses were harvested after another 24 h and clarified by low-speed centrifugation (2000 rpm for 10 min). Viruses were then aliquoted and stored at -80˚C until use Wang et al., 2021a; Wang et al., 2021b) .

To generate HIV-based vectors pseudotyped with SARS-CoV-2 S glycoproteins, 5 × 10 6 HEK293T cells were plated in a 10-cm dish one day before transfection. Then, 6 μg SARS-CoV-2 S glycoprotein expressor plasmid and 6 μg pHIV-1NL4-3 ΔEnv-NanoLuc reporter construct were transfected into the HEK293T cells using Polyethylenimine (Polysciences). Cell supernatants containing pseudoviruses were harvested 48 h after transfection and clarified by low-speed centrifugation (2000 rpm for 10 min). Viruses were then aliquoted and stored at -80˚C until use.

HEK293T cells were transfected to produce VSV-and HIV-based particles pseudotyped with SARS-CoV-2 S glycoprotein variants, as described above. To prepare viral particles, cell supernatants were collected, centrifuged at low speed (2000 rpm) to remove cell debris, and pelleted at 18,000 x g for 1 h at 4°C. In parallel with harvesting the pseudoviruses from the cell supernatants, cells were washed and lysed using 1.5% Cymal-5 at 4˚C for 10 min. Cell lysates were then clarified by highspeed centrifugation (18,000 x g for 10 min). Cell lysates and virions were analyzed by Western blotting with the following primary antibodies: rabbit anti-SARS-Spike S1 S, S1, and S2 band intensities from unsaturated Western blots were calculated using ImageJ Software. S1/S2 ratios represent the ratios of the intensities of the S1 and S2 glycoprotein bands in the Western blots. The values for the processing index of mutant S glycoproteins were calculated as follows: Processing index = (S1/S × S2/S)mutant ÷ (S1/S × S2/S)WT.

SARS-CoV-2 S glycoproteins in cell lysates or on pseudovirus particles were prepared as described above. Protein samples were boiled in 1 × denaturing buffer and incubated with PNGase F or Endo Hf (New England Biolabs, Ipswich, MA) for 1 h at 37°C according to the manufacturer's protocol. The samples were then analyzed by SDS-PAGE and Western blotting as described above.

Authentic SARS-CoV-2 viruses were obtained from BEI Resources (NIAID, NIH) and propagated for one passage on Vero-E6 cells. To prepare viral particles, cell supernatants were collected, centrifuged at low speed (2000 rpm, 10 min) to remove cell debris, and pelleted at 18,000 x g for 1 h at 4°C. Viral particles then were treated with 1% Triton X-100 and incubated with PNGase F or Endo Hf (New England Biolabs, Ipswich, MA) for 1 h at 37°C according to the manufacturer's protocol. Virions were J o u r n a l P r e -p r o o f analyzed by Western blotting with the following primary antibodies: rabbit anti-SARS-Spike S1 (SinoBiological, Cat# 40591-T62), rabbit anti-SARS-Spike S2 (SinoBiological, Cat# 40590-T62), and SARS-CoV-2 Nucleocapsid Protein Monoclonal Antibody (CliniSciences, Cat# bsm-41414M). The Western blots were developed with the following secondary antibodies: HRP-conjugated anti-rabbit antibody (Cytiva, Marlborough, MA (NA934-1ML)) or HRP-conjugated goat antimouse antibody (Jackson ImmunoResearch, West Grove, PA (Cat# 115-035-008)).

The pseudoviruses were freshly prepared as described above, without freezing and thawing. The pseudovirus preparations were incubated with target cells seeded in 96well plates at a density of 3 × 10 4 cells/well. The target cells were processed as described below.

For VSV-based pseudoviruses, the target cells were cultured for 16-24 hours after infection and then harvested to measure the luciferase activity (Promega, Madison, WI (Cat# E4550)). For HIV-based pseudoviruses, the target cells were cultured for 2-3 days after infection and then cells were harvested to measure the NanoLuc luciferase activity (Promega, Cat# N1120). For authentic SARS-CoV-2 variants, the virus infectious titers were determined by end-point dilution, monitoring cytopathic effects (CPE) on Vero-E6 target cells.

To measure viral stability at different temperatures, pseudoviruses were incubated on ice, at 4˚C, at room temperature and at 37˚C for different lengths of time J o u r n a l P r e -p r o o f prior to measuring their infectivity. Authentic SARS-CoV-2 variants were incubated at 4˚C for different lengths of time prior to measuring their infectivity, as described above.

To measure the infectivity of pseudovirus variants on target cells expressing different levels of human ACE2, several dilutions from 1 µg to 0.001 µg of human ACE2 expressor plasmid (Addgene, Watertown, MA (Cat# 1786)) were transfected into 293T cells in 12-well plates using 1 mg/ml PEI. Two days after transfection, cells were trypsinized and used as target cells for measuring the infectivity of VSV pseudotypes. In parallel, ACE2 expression in the transfected cells was measured by FACS and Western blotting, as described below.

For the FACS analysis of ACE2 expression, cells were incubated with a goat anti-ACE2 primary antibody (R&D Systems, Minneapolis, MN (Cat# AF933)), followed by an Alexa 488-conjugated donkey anti-goat secondary antibody (Invitrogen, Cat# A32814). Cells were washed 3 times with FACS buffer (2% FBS in PBS) before each antibody incubation step. Finally, cells were resuspended and ACE2 expression on the cell surface was quantified on a BD FACSCanto TM flow cytometer.

For the Western blot analysis of ACE2 expression, cells were washed and lysed in PBS containing 1.5% Cymal-5 for 10 min. Cell lysates were then clarified by highspeed centrifugation (18,000 x g for 10 min) before being analyzed by Western blotting with a goat anti-ACE2 primary antibody (R&D Systems, Cat# AF933) and an HRPconjugated mouse anti-goat secondary antibody (Invitrogen, Cat#31400).

For the alpha-complementation assay measuring cell-cell fusion (Fig. 3A, left panel) , COS-1 effector cells were plated in black-and-white 96-well plates and then cotransfected with a plasmid expressing alpha-gal and either pcDNA3.1 or the SARS-CoV-1 S glycoprotein variant at a 1:1 ratio, using Effectene according to the manufacturer's protocol. At the same time, 293T target cells in 6-well plates were cotransfected with plasmids expressing omega-gal and ACE2 at a 1:1 ratio, using Effectene. Forty-eight hours after transfection, target cells were scraped and resuspended in medium. Medium was removed from the effector cells, and target cells were then added to effector cells (one target-cell well provides sufficient cells for 50 effector-cell wells). Plates were spun at 500 x g for 3 min and then incubated at 37˚C in 5% CO2 for 10 h. Medium was aspirated and cells were lysed in Tropix lysis buffer (Thermo Fisher Scientific). The β-galactosidase activity in the cell lysates was measured using the Galacto-Star Reaction Buffer Diluent with Galacto-Star Substrate (Thermo Fisher Scientific), following the manufacturer's protocol.

For the alpha-complementation assay shown in Fig. S1 , 293T target cells in 6well plates were cotransfected with serially diluted ACE2 plasmid and 0.2 µg plasmid expressing omega-gal using Effectene.

For the cell-cell fusion assay shown in Fig. 3A , right panel, 293T effector cells in 6-well plates were cotransfected with plasmids expressing HIV-1 Tat and ACE2 at a 1:1 ratio, using PEI. Twenty-four hours after transfection, 293T effector cells and TZM-bl cells stably expressing human ACE2 were trypsinized and cocultured at a ratio of 2:1 in black-and-white 96-well plates in quadruplicate. The cocultured cells were J o u r n a l P r e -p r o o f incubated at 37˚C in 5% CO2 for an additional 48 h before luciferase activity was measured.

Fifty nanograms of S2P trimer was coated on each well of an ELISA plate at 4°C overnight. Then the plates were blocked with 300 µL of blocking buffer (1% BSA and 10% bovine calf serum in PBS) at 37°C for 2 h. Afterwards, serially diluted sACE2-Fc, convalescent serum, or moderna vaccinee serum was added and incubated at 37°C for 1 h. Next, 100 µL per well of 10,000-fold diluted Peroxidase AffiniPure goat antihuman IgG (H+L) antibody (Jackson ImmunoResearch) was added and incubated for 1 h at 37°C. Between each step, the plates were washed with PBST three times.

Finally, the TMB substrate (Sigma, St. Louis, MO) was added and incubated for 5 min at room temperature before the reaction was stopped using 1 M sulfuric acid.

Absorbance was measured at 450 nm. S1 shedding from spike trimers VSV particles pseudotyped with S glycoprotein variants were prepared as described above. To evaluate spontaneous S1 shedding at different temperatures, the cell supernatants containing pseudoviruses were incubated on ice and at 4°C, at room temperature and 37˚C for 48 h. Authentic SARS-CoV-2 variants were incubated at 4˚C for 1 day and 2 days. Virus particles were then pelleted at 18,000 x g for 1 h at 4°C.

The pelleted samples were resuspended in 1 X LDS sample buffer (Invitrogen, Cat# NP0008) and analyzed by Western blotting. To evaluate soluble ACE2-induced S1

shedding, the cell supernatants containing pseudovirus particles were incubated with soluble ACE2 at different concentrations on ice for 1 h. Afterwards, virus particles were J o u r n a l P r e -p r o o f pelleted at 18,000 x g for 1 h at 4°C. The pelleted virus particles were washed twice with cold PBS before the samples were resuspended in 1 X LDS sample buffer and analyzed by Western blotting. S1, S2 and NP were detected as described above;

soluble ACE2 bound to the pseudovirus particles was detected with a goat anti-ACE2 primary antibody (R&D Systems, Cat# AF933) and an HRP-conjugated rabbit antigoat secondary antibody (Invitrogen, Cat#31400).

We evaluated the neutralization of pseudoviruses by sACE2.v2.4, six sera collected from March to June 2020 from New York City patients that recovered from COVID-19 and six sera from Moderna vaccinees (Wang et al., 2021b) . Pseudovirus neutralization assays were performed by incubating VSV vectors pseudotyped by S glycoprotein variants with serial dilutions of sACE2.v2.4, convalescent sera from COVID-19 patients or vaccinee sera in triplicate in 96-well plates for 1 h at 37˚C. Approximately 3 x 10 4 target cells (Vero-E6 or 293T-ACE2 cells) per well were then added. The cultures were maintained for an additional 16-24 h at 37˚C before luciferase activity was measured as described above. Neutralization activity was calculated from the reduction in luciferase activity compared with mock-treated controls.

For the authentic SARS-CoV-2 neutralization assay, serially diluted serum samples starting from 1:100 were incubated with the SARS-CoV-2 preparation for 1 hour at 37˚C in triplicate. Then, the virus-serum mixture was transferred to Vero-E6 cells that had been grown overnight in 96-well plates. The multiplicity of infection of the uninhibited virus preparation was 0.1. The cells were incubated for 3 days before the cytopathic effects of viral infection were visually scored for each well in a blinded J o u r n a l P r e -p r o o f fashion by two independent observers. The results were then converted into percentage neutralization at a given serum dilution.

The concentrations of sACE2.v2.4 and serum titers that inhibit 50% of infection (the IC50 and ID50 values, respectively) were determined by fitting the data in fiveparameter dose-response curves in GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA).

Evaluations of statistical significance were performed employing Student's unpaired or paired t test using GraphPad Prism 8 software. Levels of significance are indicated as follows: *p<0.05; **p<0.01; ***p<0.001; and ****p<0.0001. EC50, IC50 and ID50 values were determined by fitting the data in five-parameter dose-response curves in GraphPad Prism 8. Western blot data were analyzed by Image Lab and ImageJ software. FACS analysis was performed by a BD FACSCanto TM flow cytometer and data was analyzed using FlowJo 10 software. All data presented in this manuscript are representative of mean values derived from at least two independent experiments. J o u r n a l P r e -p r o o f T o t a l = 1 2 7 3 L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d L e g e n d 

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Science Brief: Emerging SARS-CoV-2 Variants

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK

Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity

Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Characteristics of SARS-CoV-2 and COVID-19

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

SARS-CoV-2 vaccines in development

Fast-spreading U.K. virus variant raises alarms

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv

Mechanistic elements of protein cold denaturation

The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques

The HIV-1 gp120 major variable regions modulate cold inactivation

Brief report: New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil

Development of vaccines for SARS-CoV-2. F1000Res 9

Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Cold denaturation of proteins

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv

N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2

The hydrophobic effect: a new insight from cold denaturation and a two-state water structure

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Structural impact on SARS-CoV-2 spike protein by D614G substitution

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus